Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer
Authors:
- 7 December 2024
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 210 (1) , 179-189
Abstract
Purpose While MEK inhibitors demonstrated activity in metastatic triple negative breast cancer (mTNBC) preclinical studies, preclinical, and clinical studies implicate rapid development of resistance limiting clinical benefit. The purpose of this study was to determine response rate for Trametinib alone and in combination with Uprosertib in patients with mTNBC previously treated with chemotherapy. Methods This was an open-label, two-part, phase II, single-arm, multicenter study. Patients first received Trametinib monotherapy (2 mg daily; Part I) then at progression transitioned to Trametinib (1.5 mg) plus Uprosertib (50 mg; Part II). Results Between October 2013 and January 2017, 37 patients were enrolled to Part I. Subsequently, 19 patients entered Part II. Of the 37 patients receiving Trametinib monotherapy, 2 patients achieved partial response (PR) for an ORR of 5.4% (2/37) and an additional 6/37 (16.2%) achieved stable disease (SD). The clinical benefit rate (PR+SD) for patients receiving monotherapy was 21.6% (8/37). Of the 19 patients in Part II, 3 patients achieved PR for an ORR to Part II of 15.8% (3/19) and an additional 3 achieved SD. Median progression-free survival (PFS) was 7.7 weeks for Part I and 7.8 weeks for Part II. Circulating tumor DNA (ctDNA) clearance at C2D1 of Trametinib monotherapy was associated with improved PFS and overall survival. Conclusion In patients with mTNBC, Trametinib monotherapy demonstrated limited efficacy and addition of Uprosertib was associated with numerically greater objective responses but no difference in PFS. Translational analyses suggest ctDNA clearance as a potential early biomarker of response.Keywords
Funding Information
- National Cancer Institute (UH3CA239105, P30CA016058)
- Pelotonia
- National Institutes of Health (No. HHSN261201100070C)
This publication has 49 references indexed in Scilit:
- Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes studyAnnals of Oncology, 2022
- MEK inhibitor resistance mechanisms and recent developments in combination trialsCancer Treatment Reviews, 2021
- Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survivalAnnals of Oncology, 2020
- Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint InhibitionCell, 2020
- Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumorsCancer Chemotherapy and Pharmacology, 2020
- Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancerGynecologic Oncology, 2019
- Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II StudyClinical Lymphoma Myeloma and Leukemia, 2019
- Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignanciesCancer, 2016
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- How basal are triple‐negative breast cancers?International Journal of Cancer, 2008